SG11201703188QA - Indole carboxamides compounds useful as kinase inhibitors - Google Patents

Indole carboxamides compounds useful as kinase inhibitors

Info

Publication number
SG11201703188QA
SG11201703188QA SG11201703188QA SG11201703188QA SG11201703188QA SG 11201703188Q A SG11201703188Q A SG 11201703188QA SG 11201703188Q A SG11201703188Q A SG 11201703188QA SG 11201703188Q A SG11201703188Q A SG 11201703188QA SG 11201703188Q A SG11201703188Q A SG 11201703188QA
Authority
SG
Singapore
Prior art keywords
kinase inhibitors
compounds useful
indole carboxamides
carboxamides compounds
indole
Prior art date
Application number
SG11201703188QA
Other languages
English (en)
Inventor
Saleem Ahmad
Joseph A Tino
John E Macor
Andrew J Tebben
Hua Gong
Qingjie Liu
Douglas G Batt
Khehyong Ngu
Scott Hunter Watterson
Weiwei Guo
Bertrand Myra Beaudoin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201703188QA publication Critical patent/SG11201703188QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201703188QA 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors SG11201703188QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
PCT/US2015/057055 WO2016065226A1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
SG11201703188QA true SG11201703188QA (en) 2017-05-30

Family

ID=54427877

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201703188QA SG11201703188QA (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors
SG10201903579SA SG10201903579SA (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors
SG10201903578VA SG10201903578VA (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201903579SA SG10201903579SA (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors
SG10201903578VA SG10201903578VA (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors

Country Status (34)

Country Link
US (8) US9688629B2 (fr)
EP (2) EP3209656B1 (fr)
JP (1) JP6517928B2 (fr)
KR (2) KR102030305B1 (fr)
CN (2) CN107108583B (fr)
AR (2) AR102426A1 (fr)
AU (2) AU2015335694B2 (fr)
CA (1) CA2965517C (fr)
CL (1) CL2017000992A1 (fr)
CO (1) CO2017004481A2 (fr)
CY (2) CY1123401T1 (fr)
DK (2) DK3461821T3 (fr)
EA (2) EA032277B1 (fr)
ES (2) ES2795366T3 (fr)
HR (2) HRP20200819T1 (fr)
HU (2) HUE050592T2 (fr)
IL (2) IL251797B (fr)
LT (2) LT3461821T (fr)
MA (2) MA40301B1 (fr)
ME (2) ME03807B (fr)
MX (2) MX2017005259A (fr)
MY (2) MY195561A (fr)
PE (2) PE20170695A1 (fr)
PH (2) PH12017500725B1 (fr)
PL (2) PL3461821T3 (fr)
PT (2) PT3209656T (fr)
RS (2) RS60629B1 (fr)
SG (3) SG11201703188QA (fr)
SI (2) SI3209656T1 (fr)
TN (2) TN2017000119A1 (fr)
TW (2) TWI744218B (fr)
UY (1) UY36371A (fr)
WO (1) WO2016065226A1 (fr)
ZA (1) ZA201804893B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143768A1 (fr) 2013-03-15 2014-09-18 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de protéine bet
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
BR112016024626B1 (pt) 2014-04-23 2023-03-21 Incyte Holdings Corporation Compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7 (6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
EP3209652B1 (fr) 2014-10-24 2020-04-15 Bristol-Myers Squibb Company Composés atropisomères tricycliques
SI3210973T1 (sl) 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Heteroarilne spojine za zdravljenje oftalmičnih bolezni
CN107074804B (zh) 2014-10-24 2020-02-18 百时美施贵宝公司 咔唑衍生物
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
PE20190623A1 (es) 2016-06-20 2019-04-26 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
SI3507282T1 (sl) * 2016-09-02 2021-01-29 Bristol-Myers Squibb Company Postopek za pripravo spojin indol karboksamida
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
WO2019075386A1 (fr) 2017-10-13 2019-04-18 The Regents Of The University Of California Modulateurs de mtorc1
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
EP4234030A3 (fr) * 2018-07-13 2023-10-18 Gilead Sciences, Inc. Inhibiteurs de pd-1/pd-l1
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
KR20220110251A (ko) * 2019-12-04 2022-08-05 앱티닉스 인크. 신경변성 질환과 연관된 인지 장애를 치료하는 방법
CN115867346A (zh) * 2020-06-02 2023-03-28 Gb005股份有限公司 激酶抑制剂
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
US11708366B2 (en) 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022089620A1 (fr) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 Nouvelles formes cristallines de composé d'indole carboxamide et procédé de préparation associé
AU2022209175A1 (en) * 2021-01-12 2023-07-27 Gb005, Inc. Indole derivatives as kinase inhibitors
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023034732A1 (fr) 2021-08-30 2023-03-09 Bristol-Myers Squibb Company Composé utile pour l'imagerie tep de la tyrosine kinase de bruton
WO2023227080A1 (fr) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 Composé protac, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (fr) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline-thromboxane-synthetase
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
WO2005005429A1 (fr) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006053121A2 (fr) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
WO2006064355A2 (fr) 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
MX2007012448A (es) * 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AU2006266028B2 (en) * 2005-06-30 2012-03-15 Smithkline Beecham Corporation Chemical compounds
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
AU2007297221B2 (en) 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
EP2125819B1 (fr) * 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires
JP2010525046A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 血液系腫瘍の治療のための方法
WO2008144253A1 (fr) * 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
WO2009075830A1 (fr) 2007-12-13 2009-06-18 Merck & Co., Inc. Inhibiteurs de janus kinases
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
CN102164604A (zh) 2008-07-24 2011-08-24 百时美施贵宝公司 用作激酶调节剂的稠合杂环化合物
EP2151441A1 (fr) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Dérivés de béta-carboline en tant que substrats pour une enzyme
EP2391602B1 (fr) * 2008-12-19 2013-12-04 Bristol-Myers Squibb Company Composés carbazole carboxamide utiles comme inhibiteurs de kinases
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
EP2415184B1 (fr) 2009-02-13 2019-04-10 Nextivity, Inc. Commande à distance d'un préamplificateur
EP2440204B1 (fr) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Composés de nicotinamide utiles en tant que modulateurs de kinases
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (fr) 2010-11-03 2012-05-23 Philip Morris Products S.A. Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées
EP2640729B1 (fr) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibiteurs de la réplication du vih
TW201247627A (en) 2011-04-28 2012-12-01 Bristol Myers Squibb Co Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
EP2709997B1 (fr) 2011-05-17 2016-06-29 F.Hoffmann-La Roche Ag Inhibiteurs de tyrosine kinase de bruton
EP2729466B1 (fr) 2011-07-08 2015-08-19 Novartis AG Nouveaux dérivés de pyrrolopyrimidine
CN104662018B (zh) * 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9447039B2 (en) * 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
WO2014210087A1 (fr) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Composés de carbazole-carboxamide utiles comme inhibiteurs de kinases
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
KR102273997B1 (ko) * 2013-06-26 2021-07-08 애브비 인코포레이티드 Btk 억제제로서 1급 카복스아미드

Also Published As

Publication number Publication date
EP3461821B1 (fr) 2020-05-13
CA2965517A1 (fr) 2016-04-28
PT3209656T (pt) 2020-06-08
BR112017007956A2 (pt) 2017-12-19
UY36371A (es) 2016-04-29
WO2016065226A8 (fr) 2017-04-27
KR102001745B1 (ko) 2019-07-18
IL251797B (en) 2020-07-30
MX2017005259A (es) 2017-07-26
MA40301B1 (fr) 2019-12-31
MY188048A (en) 2021-11-12
IL262206B (en) 2020-07-30
ES2795366T3 (es) 2020-11-23
LT3209656T (lt) 2020-07-27
AR120317A2 (es) 2022-02-09
TWI744218B (zh) 2021-11-01
SI3461821T1 (sl) 2020-09-30
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
EP3209656B1 (fr) 2020-04-01
US20190248760A1 (en) 2019-08-15
EA032277B1 (ru) 2019-05-31
HUE050592T2 (hu) 2020-12-28
CN107108583A (zh) 2017-08-29
EP3461821A1 (fr) 2019-04-03
DK3209656T3 (da) 2020-07-13
US20160115126A1 (en) 2016-04-28
ZA201804893B (en) 2020-07-29
US9688629B2 (en) 2017-06-27
CL2017000992A1 (es) 2017-11-17
AR102426A1 (es) 2017-03-01
EA201892207A1 (ru) 2019-02-28
US11623921B2 (en) 2023-04-11
MY195561A (en) 2023-02-02
PE20190710A1 (es) 2019-05-17
RS60312B1 (sr) 2020-07-31
PH12020500265A1 (en) 2021-02-22
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
PE20170695A1 (es) 2017-05-26
US20170260160A1 (en) 2017-09-14
MA47043B1 (fr) 2021-09-30
KR20170061175A (ko) 2017-06-02
KR20180132167A (ko) 2018-12-11
SG10201903579SA (en) 2019-05-30
US9802915B2 (en) 2017-10-31
HRP20201146T1 (hr) 2020-10-30
EA201790740A1 (ru) 2017-08-31
AU2019283921A1 (en) 2020-01-16
US9920031B2 (en) 2018-03-20
PL3461821T3 (pl) 2020-10-19
HUE050706T2 (hu) 2020-12-28
MA40301A1 (fr) 2019-03-29
TW201630880A (zh) 2016-09-01
SI3209656T1 (sl) 2020-07-31
CY1123401T1 (el) 2021-12-31
SG10201903578VA (en) 2019-05-30
JP6517928B2 (ja) 2019-05-22
CA2965517C (fr) 2023-05-02
IL262206A (en) 2018-11-29
TN2017000119A1 (en) 2018-07-04
EA034931B1 (ru) 2020-04-08
AU2015335694A1 (en) 2017-06-08
AU2015335694B2 (en) 2020-04-02
CY1123395T1 (el) 2021-12-31
US20230192645A1 (en) 2023-06-22
AU2019283921B2 (en) 2021-01-07
JP2017531679A (ja) 2017-10-26
CN110511209A (zh) 2019-11-29
DK3461821T3 (da) 2020-08-17
NZ731946A (en) 2021-02-26
US10329274B2 (en) 2019-06-25
US20200165222A1 (en) 2020-05-28
CN107108583B (zh) 2020-11-13
ES2809974T3 (es) 2021-03-08
CO2017004481A2 (es) 2017-08-10
MX2020008024A (es) 2022-06-10
ME03740B (fr) 2021-01-20
RS60629B1 (sr) 2020-09-30
ME03807B (fr) 2021-04-20
US10604504B2 (en) 2020-03-31
EP3209656A1 (fr) 2017-08-30
HRP20200819T1 (hr) 2020-08-07
US20210107891A1 (en) 2021-04-15
CN110511209B (zh) 2022-07-05
TW201900612A (zh) 2019-01-01
US20190119245A1 (en) 2019-04-25
MA47043A1 (fr) 2021-03-31
WO2016065226A1 (fr) 2016-04-28
TN2018000218A1 (en) 2019-10-04
LT3461821T (lt) 2020-08-10
TWI743401B (zh) 2021-10-21
IL251797A0 (en) 2017-06-29
PT3461821T (pt) 2020-08-05
KR102030305B1 (ko) 2019-10-08

Similar Documents

Publication Publication Date Title
ME03740B (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HK1231411A1 (zh) 作為 抑制劑的取代的吲唑化合物
HK1231480A1 (zh) 作為 抑制劑的吲唑化合物
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
HK1232215A1 (zh) 作為醛固酮合酶抑制劑的新型二氫喹啉吡唑基化合物
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors